Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

2015141 citationsJournal Articlehybrid Open Access

Authors

A. Schreiner · Janssen (Germany)

Kaire Aadamsoo · North Estonia Medical Centre

A.C. Altamura · University of Milan

Manuel Franco · Hospital Virgen de la Concha

Philip Gorwood · Inserm

Nikolaj G. Neznanov · St.Petersburg V.M.Bekhterev Psychoneurological Research Institute

Juan Schronen

Abstract

The observed time to relapse superiority of paliperidone palmitate over oral antipsychotics provides further evidence for the value of long-acting injectable antipsychotic therapies in the treatment of schizophrenia, including during the early stages of illness.

Topics & Keywords

Schizophrenia research and treatment Parkinson's Disease Mechanisms and Treatments Obsessive-Compulsive Spectrum Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Schizophrenia Research

Volume 169, Issue 1-3, pp. 393-399

DOI: 10.1016/j.schres.2015.08.015

Field-Weighted Citation Impact: 9.27